- Masking was not possible: no time to prepare a placebo
- The study was underpowered for risk of hospitalization outcome
- Clinical assessments on day 7 were not in the initial protocol: resulted in lower sample analysis
- WHO has not established an optimal time to measure viral load or threshold reduction between the control and intervention arms
- Overrepresentation of healthcare workers (87%) may affect generalizability

University of Michigan - Ann Arbor

There were no significant differences observed between the study outcomes among the intervention versus control arms. This study was unable to determine any benefit of HCQ treatment to outpatients with mild COVID-19 beyond usual care.

Discussion from Hydroxychloroquine for Early Treatment of Adults with Mild Covid-19: A Randomized-Controlled Trial

Mitjà,O., Corbacho-Monné, M., Ubals,M. et al. Hydroxychloroquine for Early Treatment of Adults with Mild Covid-19: A Randomized-Controlled Trial, Clinical Infectious Diseases, , ciaa1009, https://doi.org/10.1093/cid/ciaa1009

Learn Before

Related